Ralph P Insinga

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation
    Ralph P Insinga
    Department of Health Economic Statistics UG1C 60, Merck Research Laboratories, PO Box 1000, North Wales, PA 19454 1099, USA
    Vaccine 26:128-39. 2007
  2. ncbi Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance
    Ralph P Insinga
    Merck and Co, Inc, UG1C 60, PO Box 1000, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 20:287-96. 2011
  3. ncbi Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cancer Epidemiol Biomarkers Prev 16:709-15. 2007
  4. ncbi Abnormal outcomes following cervical cancer screening: event duration and health utility loss
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, Pennsylvania, USA
    Med Decis Making 27:414-22. 2007
  5. ncbi Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women
    Ralph P Insinga
    Merck Research Laboratories, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 19:1585-94. 2010
  6. ncbi Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation
    Ralph P Insinga
    Department of Health Economics Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Value Health 11:1022-32. 2008
  7. ncbi A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cancer Epidemiol Biomarkers Prev 17:1611-22. 2008
  8. ncbi Structural differences among cost-effectiveness models of human papillomavirus vaccines
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Expert Rev Vaccines 7:895-913. 2008
  9. ncbi Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    BMC Infect Dis 9:119. 2009
  10. ncbi Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Pharmacoeconomics 25:155-69. 2007

Detail Information

Publications30

  1. ncbi Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation
    Ralph P Insinga
    Department of Health Economic Statistics UG1C 60, Merck Research Laboratories, PO Box 1000, North Wales, PA 19454 1099, USA
    Vaccine 26:128-39. 2007
    ..S.) per quality-adjusted life year (QALY) gained for female vaccination strategies to approximately 16000 dollars /QALY for adding male vaccination with catch-up...
  2. ncbi Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance
    Ralph P Insinga
    Merck and Co, Inc, UG1C 60, PO Box 1000, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 20:287-96. 2011
    ..We describe transition probabilities for incident human papillomavirus (HPV) 16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions...
  3. ncbi Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cancer Epidemiol Biomarkers Prev 16:709-15. 2007
    ..To estimate the incidence and duration of cervical human papillomavirus (HPV)-6, HPV-11, HPV-16, and HPV-18 infections in a population of young American women...
  4. ncbi Abnormal outcomes following cervical cancer screening: event duration and health utility loss
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, Pennsylvania, USA
    Med Decis Making 27:414-22. 2007
    ....
  5. ncbi Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women
    Ralph P Insinga
    Merck Research Laboratories, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 19:1585-94. 2010
    ..We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with the risk of infection reappearance following a period of nondetection...
  6. ncbi Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation
    Ralph P Insinga
    Department of Health Economics Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Value Health 11:1022-32. 2008
    ..To examine the short-term impact of quadrivalent human papillomavirus (HPV) (types 6/11/16/18) recombinant vaccination upon HPV disease-related health-care resource utilization and costs among young women...
  7. ncbi A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cancer Epidemiol Biomarkers Prev 17:1611-22. 2008
    ..To describe prevalence and estimated attribution of human papillomavirus (HPV) types in U.S. cervical, vaginal, and vulvar precancers and cancers...
  8. ncbi Structural differences among cost-effectiveness models of human papillomavirus vaccines
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Expert Rev Vaccines 7:895-913. 2008
    ....
  9. ncbi Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    BMC Infect Dis 9:119. 2009
    ..S. population context; (2) Identify areas where additional studies are particularly needed...
  10. ncbi Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Pharmacoeconomics 25:155-69. 2007
    ..Although there are estimated to be nearly 1 million cases of herpes zoster diagnosed in the US each year, the economic costs associated with herpes zoster in the US have not been well described...
  11. ncbi Annual productivity costs due to cervical cancer mortality in the United States
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, Merck and Co Inc, North Wales, PA 19454, USA
    Womens Health Issues 16:236-42. 2006
    ..The present study estimates annual productivity costs associated with cervical cancer mortality in the United States...
  12. ncbi Pap screening in a U.S. health plan
    Ralph P Insinga
    Department of Population Health Sciences, University of Wisconsin Madison, Madison, WI, USA
    Cancer Epidemiol Biomarkers Prev 13:355-60. 2004
    ..Sporadic screening was also more prevalent than expected based on prior self-reported data. Further opportunities exist for improving screening adherence, even within traditionally less vulnerable populations...
  13. ncbi Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, Blue Bell, PA 19422, USA
    Pharmacoeconomics 23:1107-22. 2005
    ....
  14. ncbi The incidence of herpes zoster in a United States administrative database
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, Blue Bell, PA, USA
    J Gen Intern Med 20:748-53. 2005
    ..Few recent studies have reported data on the incidence of herpes zoster (HZ) in U.S. general clinical practice...
  15. ncbi The health care costs of cervical human papillomavirus--related disease
    Ralph P Insinga
    Department of Population Health Sciences, University of Wisconsin Madison, USA
    Am J Obstet Gynecol 191:114-20. 2004
    ..The purpose of this study was to examine the health care costs of cervical human papillomavirus-related disease in a US health care setting...
  16. ncbi Diagnoses and outcomes in cervical cancer screening: a population-based study
    Ralph P Insinga
    Department of Population Health Sciences, University of Wisconsin Madison, USA
    Am J Obstet Gynecol 191:105-13. 2004
    ..This study was undertaken to examine routine cervical cancer screening diagnoses and outcomes on an age-specific basis in a US population...
  17. ncbi A multi-type HPV transmission model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:2126-76. 2008
    ....
  18. ncbi Age-based programs for vaccination against HPV
    Elamin H Elbasha
    Merck Research Laboratories, Merck and Co, Inc, NorthWales, PA, USA
    Value Health 12:697-707. 2009
    ..Answering the question of which age groups are appropriate to target for catch-up vaccination with the newly licensed quadrivalent HPV vaccine (types 6/11/16/18) will be important for developing vaccine policy recommendations...
  19. ncbi Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans
    Ronald R White
    Department of Global Outcomes Research, Global Human Health, West Point, Pennsylvania, USA
    Pharmacoeconomics 27:781-92. 2009
    ..The majority of medical RU and cost burden is incurred by the elderly. Although many people with HZ may no longer be in the workforce, HZ does contribute to lost work time...
  20. ncbi The health and economic burden of genital warts in a set of private health plans in the United States
    Ralph P Insinga
    Department of Population Health Sciences, University of Wisconsin Madison, Madison, WI, USA
    Clin Infect Dis 36:1397-403. 2003
    ..On average, individual episodes of care for genital warts involved 3.1 physician visits and incurred costs of $436. These are the first age- and sex-specific estimates of the prevalence and cost of genital warts for a US health plan...
  21. ncbi Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    Gynecol Oncol 111:188-96. 2008
    ..To estimate healthcare resource utilization and costs of cervical, vulvar and vaginal cancers in a large U.S. health plan...
  22. ncbi Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease
    Erik J Dasbach
    Merck Research Laboratories, Blue Bell, PA, USA
    Epidemiol Rev 28:88-100. 2006
    ....
  23. ncbi The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Asian Pac J Cancer Prev 9:459-66. 2008
    ....
  24. ncbi Assessing incidence and economic burden of genital warts with data from a US commercially insured population
    Tracey Hoy
    HealthCore, Inc, Fifth Floor, 800 Delaware Avenue, Wilmington, DE 19801, USA
    Curr Med Res Opin 25:2343-51. 2009
    ..This study examined the incidence of and healthcare costs attributable to genital warts within a large US commercially insured, geographically dispersed population...
  25. ncbi Model for assessing human papillomavirus vaccination strategies
    Elamin H Elbasha
    Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Emerg Infect Dis 13:28-41. 2007
    ..The ICER of this strategy was $45,056 per QALY...
  26. ncbi Five-year routine cervical cancer screening rates and intervals in a US health plan
    Vernon F Schabert
    Integral Health Decisions, Inc, Santa Barbara, CA 93101, USA
    Curr Med Res Opin 24:2429-35. 2008
    ....
  27. ncbi EuroQol (EQ-5D) health utility scores for patients with migraine
    Ruifeng Xu
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    Qual Life Res 20:601-8. 2011
    ..We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity...
  28. ncbi Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women
    Eliav Barr
    Department of Vaccines and Biologics Clinical Research, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Am J Obstet Gynecol 198:261.e1-11. 2008
    ..The purpose of this study was to inform policy regarding human papillomavirus (HPV) vaccination in North America. We measured the clinical impact of HPV-6/-11/-16/-18 vaccination in North American women...
  29. ncbi Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel
    Ralph P Insinga
    Department of Population Health Sciences and the Wisconsin State Laboratory of Hygiene, University of Wisconsin-Madison, 53726-2397, USA
    J Pediatr 141:524-31. 2002
    ..CONCLUSIONS: In Wisconsin, MS/MS screening for MCAD alone appears to be cost-effective. Future analyses should examine the cost-effectiveness of alternative follow-up and treatment regimens for MCAD and other panel disorders...
  30. ncbi Response to "Use of cervical cancer screening among insured women: the extent of missed opportunities" [Health Policy 73 (2005) 194-201]
    Ralph P Insinga
    Health Policy 77:245-6. 2006